Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Modified Osteoporosis Drugs Kill Malaria Parasite in Mice

By BiotechDaily International staff writers
Posted on 20 Mar 2012
Chemical modification of the bone-resorption bisphosphonate drugs zoledronate and risedronate enables effective targeting of the elusive intraerythrocytic form of the malaria parasite Plasmodium falciparum.

The modification enables the drugs to cross the cell membrane and thereby readily enter the infected red blood cells (RBCs). Here they act as potent inhibitors of a key enzyme, geranylgeranyl diphosphate synthase (GGPPS), in isoprenoid biosynthesis, an essential survival and defense pathway for the parasite. The drugs have little effect on this pathway in human or mouse cells.

Scientists identified the modified drugs with an in vitro assay targeting the RBC form of P. falciparum in screening a library of several hundred drug compounds known to be isoprenoid biosynthesis inhibitors. Based on "growth-rescue" and enzyme-inhibition experiments, GGPPS was shown to be a major target for the most potent leads, labeled BPH-703 and BPH-811, lipophilic analogs of zoledronate and risedronate.

“We found that compounds that were really active had a very long hydrocarbon chain. These compounds can cross the cell membrane and work at very low concentrations,” said Eric Oldfield, PhD and professor of chemistry at the University of Illinois at Urbana-Champaign (UIUC; IL, USA). Compared to the parent compounds, the lipophilic analogs show enhanced binding to the target GGPPS enzyme and only the lipophilic species are active in cells.

In vivo, the drugs were effective against Plasmodium with no observed toxicity to the mice – BPH-703 and BPH-811 tested in mice both resulted in major decreases in parasitemia and 100% mouse survival.

“It’s important to find new drug targets because malaria drugs last only a few years, maybe 10 years, before you start to get resistance,” Oldfield said. Study coauthor Yonghui Zhang, research scientist in Prof. Oldfield’s lab, noted, “We are the first to show that the enzyme GGPPS is a valid target for malaria."

The study appears in the March 5, 2012, edition of the journal Proceedings of the National Academy of Sciences USA. These results are also of broader interest as they indicate that it may be possible to overcome barriers to cell penetration of existing bisphosphonate drugs in this and other systems by simple covalent modification to form lipophilic analogs that retain their enzyme-inhibition activity and are also effective in vitro and in vivo.

Related Links:
University of Illinois at Urbana-Champaign



view channel
Image: Schematic representation of HIV DART binding to two distinct antigens simultaneously, redirecting the killer T-cells to destroy HIV-1 infected cells (Photo courtesy of Duke University).

Bi-Specific Antibodies Shown to Clear Latent HIV Infections

Bi-specific antibodies or DARTS (dual-affinity re-targeting proteins) have been used to eliminate latent HIV-infection from patient samples by redirecting polyclonal T-cells to specifically engage with... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Sale of Mexican Pharmaceutical Company Expected to Boost Latin American Prescription Drug Market

The sale of a major Mexican pharmaceutical company to an international generic drug corporation is expected to accelerate the growth of the Latin American market for prescription drugs. Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel) announced that it has entered into definitive agreements to buy Representaciones... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.